The Food and Drug Administration (FDA) had noted a decreased number of submissions for new drugs in 2004. This had raised FDA concern as pharmaceutical companies were slowly abandoning research for potentially life-saving drugs. The decreased interest of companies towards research had been associated with the growing costs and complexity of clinical trials. Read More